AbbVie Inc. (ABBV) — Stock analysis
USDCurrent price
217,54 USD
-1,09 USD (-0.50%) today
Market signals
About AbbVie Inc.
AbbVie is a major US pharmaceutical company spun off from Abbott Laboratories in 2013. Its therapeutic portfolio includes immunology (Humira, the world's best-selling drug until 2022; Skyrizi and Rinvoq as successors post Humira patent expiry), oncology (Imbruvica, Venclexta), neuroscience and aesthetics (Botox and Juvederm, acquired with Allergan in 2020). Headquartered in North Chicago, Illinois. S&P 500 component.
What does AbbVie do?▾
AbbVie makes drugs in immunology (Humira for arthritis, Crohn's, psoriasis — replaced by Skyrizi and Rinvoq), haematological oncology (Imbruvica for leukaemia, Venclexta), neuroscience drugs and medical aesthetics products (Botox and Juvederm, acquired with Allergan in 2020).
Which exchange is AbbVie listed on?▾
AbbVie is listed on NYSE with ticker ABBV. It is a member of the S&P 500 index.
Does AbbVie pay dividends?▾
Yes. It pays a very rapidly growing quarterly dividend. Yield is typically 3–5%. It is one of the pharmaceutical companies with the highest dividend growth rate in the sector.
Analyse this stock with AI
Create a free account and get 2 credits to generate a complete analysis.
Create account · 2 free credits